Orexo AB (publ) (STO: ORX)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 664.57M |
| Revenue (ttm) | 595.70M |
| Net Income (ttm) | -105.30M |
| Shares Out | 34.51M |
| EPS (ttm) | -3.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,603 |
| Open | 19.00 |
| Previous Close | 19.28 |
| Day's Range | 18.06 - 19.12 |
| 52-Week Range | 9.18 - 24.00 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 6, 2025 |
About Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment ... [Read more]
Full Company ProfileFinancial Performance
In 2023, Orexo AB's revenue was 638.80 million, an increase of 2.32% compared to the previous year's 624.30 million. Losses were -128.30 million, -27.76% less than in 2022.
Financial StatementsNews
Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vacci...
Orexo initiates new study of OX640 in participants with allergic rhinitis
OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.
Orexo AB reports Q3 results
Orexo´s Nomination Committee for the Annual General Meeting 2025
UPPSALA, Sweden , Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises of the f...
Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
UPPSALA, Sweden , Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food and Drug Ad...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world´s most trusted provi...
Orexo: invitation to presentation of the Q2 2024 Interim Report
UPPSALA, Sweden , July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm, analysts, ...
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
UPPSALA, Sweden , May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating rate social...
Report from Orexo AB's annual general meeting, 26 April 2024
UPPSALA, Sweden, April 26, 2024 /PRNewswire/ -- Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance with the nominatio...
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
UPPSALA, Sweden , April 17, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent sp...
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
UPPSALA, Sweden, April 2, 2024 /PRNewswire/ -- On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's e...
Orexo publishes the Annual and Sustainability Report for 2023
UPPSALA, Sweden , March 28, 2024 /PRNewswire/ -- Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com . The Swedish version of the Report is als...
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
UPPSALA, Sweden , March 13, 2024 /PRNewswire/ -- Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued new senior secured callable floating rate social bonds in a...
Orexo strengthens its sustainability work by establishing a social financing framework
UPPSALA, Sweden , March 8, 2024 /PRNewswire/ -- Orexo AB (publ), ('Orexo' or the 'Company') (STO: ORX) (OTCQX: ORXOY) today announces that the Company has established a social financing framework date...
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
UPPSALA, Sweden , March 8, 2024 /PRNewswire/ -- Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier and Carnegie Investment Bank as arrangers and join...
Orexo and Sobi agree to advance feasibility study with AmorphOX
Orexo and Sobi advance collaboration after successful exploratory feasibility study with the company´s world-class drug delivery platform, AmorphOX® The feasibility study confirmed that the biomolecul...
Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC
OX640 is Orexo's nasal epinephrine powder product for the acute treatment of severe allergic reactions including anaphylaxis, based on the company´s proprietary drug delivery platform, AmorphOX® The A...
Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose
OX124 is based on Orexo´s world-class drug delivery platform, amorphOX®, and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Synthetic opioids are behind 91...
Orexo announces changes in the company´s Board of Directors
UPPSALA, Sweden , Oct. 27, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medic...
Orexo´s Nomination Committee for the Annual General Meeting 2024
UPPSALA, Sweden , Oct. 26, 2023 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2024, that will take place on April 26, a Nomination Committee has been appointed. The shareholders having ...
Report from Orexo´s extraordinary general meeting
STOCKHOLM , Oct. 26, 2023 /PRNewswire/ -- Election of new member of the board of directors The extraordinary general meeting in Orexo AB (publ) on 26 October 2023 resolved, in accordance with the nomi...
Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids
The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US The study demonstrated no statistically significant difference between treatment arms in ...
Notice of Extraordinary General Meeting in Orexo AB (publ)
UPPSALA, Sweden, Oct. 3, 2023 /PRNewswire/ -- Orexo AB (publ), Reg. No. 556500-0600, with its registered office in Uppsala, gives notice of the Extraordinary General Meeting to be held on 26 October 2...